An appraisal of golimumab in the treatment of severe, active nonradiographic axial spondyloarthritis

Julien Paccou, René-Marc Flipo Department of Rheumatology, Lille University Hospital, Lille, France Abstract: Golimumab (Simponi®) is a fully human tumor necrosis factor α inhibitor (TNFi) antibody administered subcutaneously. In the European Union, golimumab is indica...

Full description

Bibliographic Details
Main Authors: Paccou J, Flipo RM
Format: Article
Language:English
Published: Dove Medical Press 2016-07-01
Series:Drug Design, Development and Therapy
Subjects:
Online Access:https://www.dovepress.com/an-appraisal-of-golimumab-in-the-treatment-of-severe-active-nonradiogr-peer-reviewed-article-DDDT